|
**Overview**: Cancer 50 Gene Panel**Introduction**: The Cancer 50 Gene Panel is a diagnostic tool designed to screen for cancer-related mutations using FFPE tissue samples. In India, cancer burden is high (~1.4 million new cases/year), with targeted therapy eligibility (e.g., EGFR, KRAS, BRAF in lung/colorectal/thyroid cancers) depending on 50-gene hotspot mutations. High morbidity from underdiagnosis of actionable mutations in rural/low-SES patients, limited NGS labs, delayed targeted therapy leading to poor outcomes. Per molecular pathology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs NGS for mutation analysis over 1-2 days with high sensitivity/specificity, valuable for precision oncology in solid tumors. This diagnostic falls under genetic cancer screening and targets tumor tissue from cancer patients, addressing accurate detection to guide targeted drugs or clinical trials. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise treatment selection and improving survival. Its FFPE-based approach ensures reliable detection.**Other Names**: Cancer 50 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.**Historical Milestone**: NGS panels expanded; in India, growing in cancer centers.**Purpose**: The test screens for 1 parameter (50 cancer gene mutation analysis) to guide cancer assessment, identify actionable mutations, inform targeted therapy.**Test Parameters**: 1. 50 Cancer Gene Mutation Analysis.**Pretest Condition**: No fasting required; patients should have confirmed cancer diagnosis with FFPE tissue available.**Specimen**: FFPE tissue block (0.5-2 cm³), transported within specified times to maintain sample viability.Sample Stability: Indefinite when properly stored (paraffin-embedded blocks stable long-term).**Medical History**: Patients should provide details on cancer type, stage, prior therapy, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated actionable mutations including poor response, benefits of profiling, and minimal discomfort (tissue already collected).**Procedural Considerations**: The test involves sample processing using NGS by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Poor tissue quality, low tumor content, or delays can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Actionable mutations indicate targeted therapy eligibility, necessitating specialist input. No mutations may require follow-up.**Specialist Consultation**: Medical oncologists should be consulted for management.**Additional Supporting Tests**: IHC or FISH for confirmation.**Test Limitations**: Covers hotspots only; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, NGS Studies India 2023. |
